Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy
| Autor: | B Heymer, Gero Massenkeil, G.-R. Burmester, Hartmut Radtke, Andreas Radbruch, Oliver Rosen, Falk Hiepe, S Pest, Steffen Hauptmann, Andreas Thiel, Renate Arnold |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Oncology
medicine.medical_specialty Systemic disease Cyclophosphamide medicine.medical_treatment Pulmonary Fibrosis Cardiomyopathy Transplantation Autologous Scleroderma Autologous stem-cell transplantation Internal medicine medicine Humans Transplantation Chemotherapy Scleroderma Systemic business.industry Myocardium Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Connective tissue disease Fibrosis Surgery Death Female business Cardiomyopathies medicine.drug |
| Zdroj: | Bone marrow transplantation. 27(6) |
| ISSN: | 0268-3369 |
| Popis: | In patients with systemic sclerosis (SSc) treatment-related mortality after autologous stem cell transplantation (ASCT) appears to be increased as compared to patients with hematological malignancies. In our phase I/II study on ASCT in autoimmune diseases a patient with SSc died on day 2 after ASCT. Here we report the results of the autopsy which revealed advanced pulmonary and cardiac fibrosis as the most probable cause of death. In spite of detailed technical examination before enrollment, the cardiopulmonary function tests did not reflect the advanced stage of the disease. We conclude that in selected patients with SSc, biopsies should be performed to reduce mortality after ASCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|